Richter’s uterine fibroid drug OK’d for long-term use
Gedeon Richter announced today that its drug Esmya was approved by European Commission officials for long-term management of uterine fibroids. The drug had already been approved for pre-operative treatment of symptoms from uterine fibroids.
According to a press release from Gedeon Richter, the approval came after several levels of successful clinical trials.
"The present extension of indication adding the intermittent treatment courses of Esmya provides an opportunity to women to benefit from long-term medical management of uterine fibroids and to potentially avoid surgery," the release said. "Uterine fibroids are the most common benign, solid tumours of the female genital tract, affecting between 20% and 40% of women of reproductive age."
Gedeon Richter is Hungaryʼs leading drug company and a major pillar in the Budapest Stock Exchange, with a reported market capitalisation of €2.1 billion in 2014. The company boasts the largest research and development unit in Central and Eastern Europe.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.